Skip to main content

Table 1 Number of exams available (for a total of 162 women) at each treatment time point (with the number of cases with a recurrence vs.no recurrence in parentheses)

From: Most-enhancing tumor volume by MRI radiomics predicts recurrence-free survival “early on” in neoadjuvant treatment of breast cancer

 

Exams with at least 3 acquisitions*

Functional Tumor Volume

Both

Pre-treatment baseline

141 (40 vs. 101)

137 (39 vs. 98)

137 (39 vs. 98)

Early treatment

142 (37 vs. 105)

143 (38 vs. 105)

141 (37 vs. 104)

Both at baseline and early treatment

127 (37 vs. 90)

124 (26 vs. 88)

123 (36 vs. 87)

  1. *For automated tumor segmentation, a dynamic contrast-enhanced MR exam needed at a minimum to consist of a pre-contrast and two post-contrast images; At baseline, all available exams met this criterion while at early treatment a single exam was eliminated from our automated analysis